GENE ONLINE|News &
Opinion
Blog

2022-05-31| Trials & Approvals

Sanofi’s Trial to Make Cialis Available Over-the-Counter Meets FDA Hold

by Joy Lin
Share To

The FDA has imposed a clinical hold on Sanofi’s actual use trial (AUT) that evaluates switching Cialis (tadalafil), a prescription-only medication for erectile dysfunction, to an over-the-counter version. The reason for the pause appears to be related to the protocol design of the trial. 

The AUT has yet to recruit any patients. Sanofi will continue to work with the FDA to resolve the hold, said the company. 

Related article: Cell and Gene Therapy Landscape in Japan is Moving Beyond Oncology 

 

A Popular Prescription Treatment for Erectile Dysfunction

 

Cialis (tadalafil) is one of the most popular prescription medications for erectile dysfunction. The drug was first approved by the European Medicines Agency in 2002. An approval from the US FDA followed in 2003. 

Cialis is a PDE-5 inhibitor, a type of medication that causes vasodilation and improves blood flow to tissues such as the tissue of the penis. It works by inhibiting the PHE-5 enzyme found in the smooth muscle cells of blood vessels. 

In 2014, Sanofi bought exclusive rights to market the OTC version of Cialis from Eli Lilly. The French drugmaker planned to apply for OTC approval in the US, Australia, Canada, and Europe once the drug patent expired in 2018. 

While rival medication Viagra has made the switch to OTC in the UK (but not the US), Cialis remains a prescription medicine. The drug may be well-tolerated, with common side effects being headaches, nasopharyngitis, muscle aches, and back pain, but concerns exist over the potential of misuse and drug interactions. 

Like Viagra, Cialis has the potential to lower blood pressure to dangerous levels, and cannot be taken with nitrates such as chest pain medications or recreational drugs such as amyl or butyl nitrite. It is also not for women or children. 

The FDA’s process for transferring prescription drugs to OTC status is rigorous and highly regulated. For Cialis to be granted OTC status, it must have a wide safety margin, be effective, and be labeled clearly to ensure proper use.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
FDA Requests for a $7.2 Billion Budget in FY 2025 for Critical Health Initiatives
2024-03-12
Wegovy Expands Its Reach: First Weight-Loss Medication Approved to Reduce Cardiovascular Risk
2024-03-11
LATEST
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
EVENT
Scroll to Top